UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, DC 20549
SCHEDULE 14A
(Rule 14a-101)
INFORMATION REQUIRED IN PROXY STATEMENT
SCHEDULE 14A INFORMATION
Proxy Statement Pursuant to Section 14(a) of
the Securities Exchange Act of 1934 (Amendment No. )
Filed by the Registrant x Filed by a Party other than the Registrant ¨
Check the appropriate box:
| ¨ | Preliminary Proxy Statement |
| ¨ | Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) |
| ¨ | Definitive Proxy Statement |
| ¨ | Definitive Additional Materials |
| x | Soliciting Material Pursuant to §240.14a-12 |
Covidien Ltd.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement, if other than the Registrant)
Payment of Filing Fee (Check the appropriate box):
| x | No fee required. |
| ¨ | Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11. |
| (1) | Title of each class of securities to which transaction applies: |
| (2) | Aggregate number of securities to which transaction applies: |
| (3) | Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined): |
| (4) | Proposed maximum aggregate value of transaction: |
| (5) | Total fee paid: |
| ¨ | Fee paid previously with preliminary materials. |
| ¨ | Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing. |
| (1) | Amount Previously Paid: |
| (2) | Form, Schedule or Registration Statement No.: |
| (3) | Filing Party: |
| (4) | Date Filed: |
Covidien Ltd. to Hold Special General Meeting of Shareholders
HAMILTON, Bermuda—April 8, 2009 – Covidien Ltd. (NYSE: COV, BSX: COV) today announced that it will hold a special general meeting of shareholders on May 28, 2009 in connection with the proposed reorganization to effectively change the place of incorporation of the company from Bermuda to Ireland. The meeting will convene at 10:00 a.m. ET in the Company’s offices at 15 Hampshire Street, Mansfield, MA.
A definitive proxy statement for the shareholders’ meeting will be filed with the Securities and Exchange Commission (SEC) and is expected to be mailed on or about April 24, 2009 to all shareholders of Covidien Ltd. as of April 17, 2009, the record date for the special shareholders’ meeting. During the meeting, shareholders will vote on the proposals listed in the proxy statement. Additional information on the reorganization, including associated benefits and risks, will be contained in the definitive proxy statement.
Covidien will, upon completion of the Transaction, continue to be subject to SEC reporting requirements, and Covidien’s shares will continue to be listed on the New York Stock Exchange under the symbol “COV.”
This communication is being made in respect of the proposed reorganization. In connection with the reorganization, Covidien intends to file with the SEC a proxy statement and mail the proxy statement to its shareholders. Shareholders are urged to read such proxy statement when it becomes available because it will contain important information. The proxy statement will be, and other documents filed or to be filed by Covidien with the SEC are or will be, available free of charge at the SEC’s web site (www.sec.gov) and at Covidien’s web site (www.covidien.com).
Covidien and its directors and executive officers and other persons may be deemed participants in the solicitation of proxies in connection with the proposed reorganization. Information about the direct or indirect interests of the participants, by security holdings or otherwise, is available in Covidien’s Annual Report on Form 10-K for the year ended September 26, 2008 and proxy statement for Covidien’s 2009 annual meeting, which were filed on November 21, 2008 and January 22, 2009, respectively, and will be available in the proxy statement to be filed and mailed to shareholders in connection with the reorganization.
ABOUT COVIDIEN
Covidien is a leading global healthcare products company that creates innovative medical solutions for better patient outcomes and delivers value through clinical leadership and excellence. Covidien manufactures, distributes and services a diverse range of industry-leading product lines in four segments: Medical Devices, Imaging Solutions, Pharmaceutical Products and Medical Supplies. With 2008 revenue of nearly $10 billion, Covidien has more than 41,000 employees worldwide in 59 countries, and its products are sold in over 140 countries. Please visit www.covidien.com to learn more about our business.
| CONTACTS:
Eric Kraus Senior Vice President Corporate Communications 508-261-8305 eric.kraus@covidien.com |
Coleman Lannum, CFA Vice President Investor Relations 508-452-4343 cole.lannum@covidien.com | |
| Bruce Farmer Vice President Public Relations 508-452-4372 bruce.farmer@covidien.com |
Brian Nameth Director Investor Relations 508-452-4363 brian.nameth@covidien.com | |